<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34151660</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>3-4</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>What is amyotrophic lateral sclerosis prevalence?</ArticleTitle><Pagination><StartPage>203</StartPage><EndPage>208</EndPage><MedlinePgn>203-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.1936557</ELocationID><Abstract><AbstractText><i>Objective:</i> To assess amyotrophic lateral sclerosis (ALS) prevalence and to analyze how this estimate vary according to the historical depth of data collection. <i>Methods:</i> Data from the PARALS register have been used. Crude prevalence ratio was estimated on 31 December 2015 for the period 2015-2013 and then repeated extending the time interval by 3 years each time. For each time interval, prevalence ratio was calculated globally and stratified by sex, age at diagnosis, and phenotype. Prevalence was also calculated considering patients who underwent tracheostomy during the same study period. <i>Results:</i> Prevalence ratios increased proportionally to the length of the time period considered, ranging from 6 (95% CI 5.3-6.7) for a 3-year period to 12.1 (95% CI 11.1-13.1) per 100,000 population for a 21-year period. Prevalence ratio increase was inversely proportional to age at diagnosis, being null in the &gt;85 years class and maximal in the 25-35 age class (+1700%). Among phenotypes, predominant UMN showed the highest increase (from 0.5, 95% CI 0.3-0.8, to 2.1, 95% CI 1.7&#x2009;-&#x2009;2.6, +320%). <i>Discussion</i>: Because of the variability of ALS survival, prevalence ratio strongly depends on the length of the follow-up period. A 12-year period should be sufficient to get a reliable estimate of ALS prevalence including long-survival patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0393-4736</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palumbo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cugnasco</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, ALS Center, Azienda Ospedaliero Universitaria Maggiore della Carit&#xe0;, and University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, ALS Center, Azienda Ospedaliero Universitaria Maggiore della Carit&#xe0;, and University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xd2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9579-5341</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience "Rita Levi Montalcini", ALS Center, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PIEMONTE AND VALLE D&#x2019;AOSTA REGISTER FOR ALS (PARALS)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014139" MajorTopicYN="N">Tracheostomy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">burden</Keyword><Keyword MajorTopicYN="N">cohort studies</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>21</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34151660</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.1936557</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>